- Marketwired•2 years ago
Aastrom Biosciences, Inc. , a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the change of its corporate name to ...
- Zacks Small Cap Research•2 years ago
We rates shares of Aastrom Biosciences, Inc. (ASTM) a 'Buy' and are adjusting our target to $6.50 per share. Based on industry-average multiples, we see Aastrom's stock doubling in 2015. On November 13, 2014, Aastrom Biosciences reported financial results for the quarter of 2014 ending September 30, 2014. Results in the quarter included a full quarter of operations for the recently acquired Cell Therapy and Regenerative Medicine ("CTRM") business from Sanofi (SNY), previously known as Genzyme Biosurgery Aps.
- theflyonthewall.com•2 years ago
Aastrom Biosciences announced the appointment of Gerard Michel as CFO and vice president, corporate development. Michel was formerly CFO and vice president, corporate development of Biodel, where he oversaw ...
NasdaqCM . Currency in USD
|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52wk Range||undefined - undefined|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||N/A|
|Avg Vol (3m)||N/A|
|Dividend & Yield||N/A (N/A)|